drug
seladelpar lysine
Marketedupdated 6mo agoby CymaBay Therapeutics Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval, with an approval for biliary liver cirrhosis.
all catalysts(2)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 14, 2029
~2.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Mar 19, 2035method-of-use (U-1854)US 10272058
- Mar 19, 2035method-of-use (U-1854)US 11406611
- Mar 19, 2035method-of-use (U-1854)US 11596614
- Mar 19, 2035method-of-use (U-1854)US 9486428
- Sep 13, 2026compositionUS 7709682
- Aug 2, 2026compositionUS 7301050
FDA exclusivities (2)
- Aug 14, 2031ODE-486Orphan Drug (7y)4.7y
- Aug 14, 2029NCENew Chemical Entity (5y)2.7y
News(2)
- Gilead reveals partial clinical hold on 2 CAR-T cell therapy trialsGilead Sciences announced on its third-quarter earnings call Oct. 29 that the company has placed a partial clinical hold on two studies for the CAR-T cell therapy KITE-753 in diffuse large B-cell l…fiercebiotech · 18d ago
- CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammati…fiercebiotech · 2mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that